1 |
J.R. Sanjuan, US and EU protection of pharmaceutical test data. Consumer Project on Technology (2006)
|
2 |
K. Hoppu, A summary of the EU paediatric initiatives. WHO Expert Consultation on Essential Medicines for Children (2007)
|
3 |
C. McCourt, E. McMahon and I. VanderElst, Amendments to the patented medicines (notice of compliance) regulations and the data protection regulations are now in force. Torys LLP (2006)
|
4 |
J. Reichman, Undisclosed clinical trial data under the TRIPS agreement and its progeny: a broader perspective. UNCTAD-ICTSD Dialogue on Moving the pro-deveopment IP agenda forward: Preserving Public Goods in health, education and learning, Bellagio (2004)
|
5 |
J. Holding, Do orphan medicines benefit patients? The Pharmaceutical Journal, 280, 216-218 (2008).
|
6 |
C.M. Correa, Ownership of knowledge-implications of the role of the private sector in pharmaceutical R&D. In: J.A.Z Bermudez and M.A. Oliveria, Intellectual Property in the Context of the WTO TRIPS Agreement, Center for Pharmaceutical Policies. Rio de Janeiro, Brazil (2004)
|
7 |
International Federation of Pharmaceutical Manufacturers & Associations(IFPMA), Data exclusivity: encouraging development of new medicines (2007)
|
8 |
W.J. Rodriguez, R. Roberts and D. Murphy, Current regulatory policies regarding pediatric indications and exclusivity. Journal of Pediatric Gastroenterology and Nutrition, 37, S40-S45 (2003).
DOI
ScienceOn
|
9 |
E. Dickinson, FDA's role in making exclusivity determinations. Food and Drug Law Journal, 54, 195-203 (1999).
|
10 |
J.R. Sanjuan, J. Love and R. Weissman, Protection of pharmaceutical test data: a policy proposal. Consumer Project on Technology (2006)
|
11 |
http://ezdrug.kfda.go.kr/kfda2.
|